Mirum Pharmaceuticals, Inc. (MIRM) SEC Filings & Earnings Calls

Clinical trial success but safety profile includes diarrhea (64% vs 11% placebo) and serious adverse events in treated patients

“Diarrhea: 16 (64.0%) vs 3 (11.1%); SAEs in MRX-treated patients: pneumonia, pyrexia, large intestine infection, acute kidney injury, viral infection with bronchiolitis; none related”

Key executive departure may cause temporary leadership gap in clinical development.

“Dr. Quan ceased as CMO effective September 2, 2026; new CMO starts September 21, 2026.”

Significant operating losses and accumulated deficit

“We have incurred significant operating losses since our inception. As of June 30, 2026, we had an accumulated deficit of $1.5 billion, compared to $667.5 million as of December 31, 2025.” · word for word

Dependence on additional financing

“We may need substantial additional financing to continue our commercialization efforts for our approved medicines, develop our product candidates, license or acquire new product candidates and approved medicines and implement our operating plans.” · word for word

Patent protection uncertainty

“We do not currently have patent protection or regulatory exclusivity for certain of our approved medicines or rely on regulatory exclusivity.” · word for word

High debt level

“As of June 30, 2026, we had $769.0 million aggregate principal amount of indebtedness under the Notes.” · word for word

FDA recommended Phase 3 study for volixibat despite positive VISTAS data, delaying NDA submission to H1 2027

“the agency recommended conducting a Phase 3 study. We intend to hold further discussions with the FDA before a potential NDA submission in the first half of 2027 based on VISTAS” · word for word

Operating expenses increased 65% YoY, significantly outpacing revenue growth

“Total operating expenses were $218.8 million for the quarter ended June 30, 2026 compared to $132.8 million” · word for word

Dilution risk if notes convert; debt service obligations.

“Notes are convertible into common stock at $138.94 per share.”

High cash burn and reliance on external financing

“Net cash used in operating activities was $228.8 million for the three months ended March 31, 2026” · word for word

Convertible note conversion risk

“the Notes are convertible at the option of the holders of the Notes during the second quarter of 2026” · word for word

Acquisition integration and milestone obligations

“we are obligated to pay up to an aggregate of $25.8 million in cash and 522,375 shares of Company common stock, subject to deduction for taxes and certain holdbacks, and up to an aggregate of $200.0 million upon achievement of certain commercial milestones.” · word for word

Regulatory and clinical development risks remain.

“Forward-looking statements caution about risks and uncertainties.”

Governance risk from classified board and supermajority provisions

“We recognize that proxy advisory firms and certain institutional investors deem these provisions to adversely impact stockholder rights. Our Nominating Committee continues to review and assess our governance framework, including our classified board structure and supermajority voting provisions, in the context of our stage of development, stockholder feedbac” · word for word

Pipeline dependency on multiple clinical readouts; failure of any key study could impact future revenue growth.

“Four potentially registrational readouts over next 18 months; volixibat VISTAS, LIVMARLI EXPAND, brelovitug AZURE studies.”

Operating expenses growing faster than revenue, potentially pressuring margins if revenue growth slows.

“Total operating expenses $543.4M (+28% YoY) vs net product sales $521.3M (+55% YoY).”

Integration risk; brelovitug Phase 3 data expected 2H2026, no guarantee of success.

“Topline Phase 3 results expected in 2H 2026.” · word for word

Dilution from stock consideration and private placement.

“Issuance of 4.67M + 0.52M shares; private placement adds shares.”

Acquisition integration risk for Bluejay Therapeutics

“failure of our acquisition of Bluejay to be completed for any reason” · word for word

Clinical trial and regulatory approval risk for pipeline candidates

“results, enrollment, conduct and progress of Bluejay’s ongoing studies; ability to obtain necessary regulatory approvals” · word for word

Generic competition risk for Livmarli, a key product, could significantly impact revenue.

“ANDA filings for generic maralixibat; patent infringement suits filed.”

Dilution from PIPE issuance; acquisition integration risk.

“Issuance of 1M new shares; acquisition of Bluejay Therapeutics pending.”

Clinical and regulatory risk for brelovitug; Phase 3 data not yet available.

“Top-line Phase 3 results expected in 2H 2026.” · word for word

Generic competition risk for Livmarli, potential revenue loss if patents are invalidated.

“Paragraph IV Notice Letter from Sandoz challenging five Livmarli patents.”

Pipeline dependency on clinical trial outcomes

“Phase 2b VISTAS topline data expected Q2 2026; VANTAGE enrollment completion in 2026”

Concentration risk on single 3PL and specialty pharmacy

“The Company relies on a single third-party logistics provider and a single specialty pharmacy for all of the Company's sales of its approved medicines in each of the U.S. and Canada” · word for word

Convertible note conversion risk

“The Company's convertible notes are convertible at the option of the holders during the fourth quarter of 2025” · word for word